Technical Analysis for SNSS - Sunesis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.5573 -2.23% -0.01
SNSS closed down 2.23 percent on Friday, January 17, 2020, on 1.18 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical SNSS trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Expansion Breakout Bullish Swing Setup -2.23%
Pocket Pivot Bullish Swing Setup -2.23%
Wide Range Bar Range Expansion -2.23%
Upper Bollinger Band Walk Strength -2.23%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including a Phase III clinical trial, known as the VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II/III trial known as the LI-1 trial in patients older than 60 years with AML or high-risk myelodysplastic syndrome. In addition, the company has completed the Phase II portion of a Phase Ib/II trial of Vosaroxin in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and Phase II trial in previously untreated patients with 60 years of age or older with AML or REVEAL-1 trial, which explored three dosing schedules of vosaroxin. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Biopharmaceutical Drugs Chemical Compounds Organic Compounds Acute Myeloid Leukemia Myelodysplastic Syndrome Orphan Drugs Lactams Treatment Of Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome

Is SNSS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.77
52 Week Low 0.1951
Average Volume 2,380,336
200-Day Moving Average 0.77
50-Day Moving Average 0.39
20-Day Moving Average 0.39
10-Day Moving Average 0.45
Average True Range 0.05
ADX 31.71
+DI 39.92
-DI 9.48
Chandelier Exit (Long, 3 ATRs ) 0.46
Chandelier Exit (Short, 3 ATRs ) 0.43
Upper Bollinger Band 0.54
Lower Bollinger Band 0.23
Percent B (%b) 1.05
BandWidth 80.25
MACD Line 0.04
MACD Signal Line 0.01
MACD Histogram 0.0249
Fundamentals Value
Market Cap 13.1 Million
Num Shares 23.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.29
Price-to-Sales 24.54
Price-to-Book 0.00
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.71
Resistance 3 (R3) 0.71 0.66 0.68
Resistance 2 (R2) 0.66 0.62 0.66 0.68
Resistance 1 (R1) 0.61 0.60 0.59 0.61 0.67
Pivot Point 0.56 0.56 0.55 0.56 0.56
Support 1 (S1) 0.51 0.52 0.48 0.51 0.45
Support 2 (S2) 0.46 0.50 0.46 0.44
Support 3 (S3) 0.41 0.46 0.43
Support 4 (S4) 0.40